600267 Zhejiang Hisun Pharmaceutical
- 7.92
- +0.15+1.93%
Zhejiang Hisun Pharmaceutical News
Announcement from Zhejiang Hisun Pharmaceutical Co., Ltd. regarding the approval of the listing application of Epobispar Emine Active Pharmaceutical Ingredient in the 'Notification of Approval of Chemical Raw Materials for Market Application'
Announcement of Subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. Obtaining New Veterinary Drug Registration Certificate.
Announcement from Zhejiang Hisun Pharmaceutical Co., Ltd. regarding its wholly-owned subsidiary obtaining approval for listing application of Efavirenz as an active pharmaceutical ingredient in the Chemical Raw Materials category.
Announcement of Subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. Obtaining New Veterinary Drug Registration Certificate.
Announcement of subsidiary pharmaceuticals passing the generic consistency evaluation by Zhejiang Hisun Pharmaceutical Co., Ltd.
Announcement of Zhejiang Hisun Pharmaceutical Co., Ltd. on its subsidiary obtaining a pharmaceutical registration certificate.
Zhejiang Hisun Pharmaceutical Co., Ltd.'s announcement in response to the Shanghai Stock Exchange's regulatory work letter regarding the company's 2023 annual report information disclosure.
Announcement of subsidiary pharmaceuticals passing the generic consistency evaluation by Zhejiang Hisun Pharmaceutical Co., Ltd.
Announcement of Subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. Obtaining New Veterinary Drug Registration Certificate.
Announcement of Zhejiang Haizheng Pharmaceutical Co., Ltd. on the delisting of “Haizheng Dingzhan” convertible bonds
Announcement of Zhejiang Haizheng Pharmaceutical Co., Ltd. on the holding of the Investor Reception Day event
Announcement of Zhejiang Haizheng Pharmaceutical Co., Ltd. on the results of the “Haizheng Transfer” resale and the change in the ratio of bondholders' convertible bonds to 10%
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Zhejiang Haizheng Pharmaceutical Co., Ltd.
Legal Opinion of Beijing Kangda (Hangzhou) Law Firm on the 2023 Annual General Meeting of Shareholders of Zhejiang Haizheng Pharmaceutical Co., Ltd.
Announcement of Zhejiang Haizheng Pharmaceutical Co., Ltd. on its subsidiary obtaining a new veterinary drug registration certificate
Announcement of Zhejiang Haizheng Pharmaceutical Co., Ltd. on its subsidiary obtaining approval documents for veterinary drug products
Zhejiang Haizheng Pharmaceutical Co., Ltd. 2023 Annual Shareholders' Meeting Information
An indicative announcement of Zhejiang Haizheng Pharmaceutical Co., Ltd. on holding the 2023 Annual General Meeting of Shareholders
Zhejiang Haizheng Pharmaceutical Co., Ltd. shareholder return plan for the next three years (2024-2026)
Zhejiang Haizheng Pharmaceutical Co., Ltd. 2023 Internal Control Evaluation Report
Analysis
Price Target
No Data
